💊 의약품 A-Z 🧬 표적 🛠 도구 📚 가이드
전체 의약품 약물 분류 치료 영역 부작용
가이드 용어집 연대표
비교 약물 체내 여정 약물 계열
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Finerenone

CHEMBL2181927 Phase 4 승인됨 Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
378.4 g/mol
LogP
2.4
Phase
4

This medication blocks a hormone receptor called the mineralocorticoid receptor, reducing inflammation and scarring in the heart and kidneys. It is used to slow the progression of chronic kidney disease in adults with type 2 diabetes and to reduce the risk of heart failure.

분자량

378.4000 g/mol

LogP

2.40

TPSA

110.00 Ų

리핀스키 5의 법칙

통과

치료 영역

Cardiovascular Disease Chronic Kidney Disease Type 2 Diabetes Hypertension Heart Failure

작용 기전

Provides an essential mineral element required for numerous enzymatic reactions, structural proteins, and physiological processes. Supplementation addresses deficiency states.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

기전

Provides an essential mineral element required for numerous enzymatic reactions, structural proteins, and physiological processes. Supplementation addresses deficiency states.

2D 구조

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CCOc1ncc(C)c2c1[C@H](c1ccc(C#N)cc1OC)C(C(N)=O)=C(C)N2

                

                

                
                

                    
InChI

                    
InChI=1S/C21H22N4O3/c1-5-28-21-18-17(14-7-6-13(9-22)8-15(14)27-4)16(20(23)26)12(3)25-19(18)11(2)10-24-21/h6-8,10,17,25H,5H2,1-4H3,(H2,23,26)/t17-/m1/s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C21H22N4O3

                    

                    
                    

                        
HBD / HBA

                        
2 / 6

                    

                    
                    

                        
회전 가능 결합

                        
5

                    

                    
                    
                    

                        
무거운 원자

                        
28

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
자주 묻는 질문

                

                    
                    

                        
                        

                            
This medication blocks a hormone receptor called the mineralocorticoid receptor, reducing inflammation and scarring in the heart and kidneys. It is used to slow the progression of chronic kidney disease in adults with type 2 diabetes and to reduce the risk of heart failure.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Provides an essential mineral element required for numerous enzymatic reactions, structural proteins, and physiological processes. Supplementation addresses deficiency states.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Finerenone is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL2181927.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 60150535.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
의학적 면책조항

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.